Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy

Sawicki, L; Kirchner, Julian; Buddensieck, Carolin; Antke, Christina; Ullrich, T.; Schimmöller, Lars; Boos, Johannes; Schleich, Christoph; Schaarschmidt, Benedikt Michael; Buchbender, Christian; Heusch, Philipp; Robert, René; Albers, Peter; Antoch, Gerald; Müller, Hans‐Wilhelm; Hautzel, Hubertus

doi:10.1007/s00259-019-04308-5

Cited by 53 publications

(32 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sensitivity values of WB-DWI and 68 Ga-PSMA PET/CT were 0.35 and 0.68 when the PSA level was 0.2-5.0, respectively, and 0.21 and 0.43 when PSA level was 0.2-2.0, respectively. 66 The prospective, multicenter, non-randomized LOCATE trial is ongoing to determine the ability of WB-MRI to detect biochemical recurrence. 67 Fig.…”

Section: Wb-dwi For Patients With Biochemical Recurrence After Definitive Local Therapymentioning

confidence: 99%

Whole‐body diffusion‐weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond

Yoshida¹,

Takahara

Arita³

et al. 2021

Int J of Urology

View full text Add to dashboard Cite

Abbreviations & Acronyms ADC = apparent diffusion coefficient ADT = androgen deprivation therapy CRPC = castration-resistant prostate cancer CT = computed tomography DWI = diffusion-weighted imaging DWIBS = diffusion-weighted whole-body imaging with background body signal suppression MET-RADS-P = METastasis Reporting and Data System for Prostate Cancer MIP = maximum intensity projection MRI = magnetic resonance imaging PET = positron emission tomography PSA = prostate-specific antigen PSMA = prostate-specific membrane antigen SPECT = single-photon emission computed tomography STIR = short-tau inversion recovery T1WI = T1-weighted imaging T2WI = T2-weighted imaging USPIO = ultrasmall superparamagnetic iron oxide WB-DWI = whole-body diffusion-weighted imaging

show abstract

Section: Wb-dwi For Patients With Biochemical Recurrence After Definitive Local Therapymentioning

confidence: 99%

Whole‐body diffusion‐weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond

Yoshida¹,

Takahara

Arita³

et al. 2021

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Whole body-MRI (WB-MRI) with the addition of diffusion weight imaging has a lower reported accuracy compared to PSMA PET-CT in the identification of bone metastases and lymph nodes (48). Although, when compared to PSMA PET-CT in the setting of biochemical relapse, WB-MRI is inferior (48) it may be of benefit in assessing response and identifying oligoprogressing lesions (59).…”

Section: Radiological Stagingmentioning

confidence: 99%

“…A post-hoc analysis of the data from the STAMPEDE patients, disease showed a similar benefit regardless of disease volume (68). Outperforms conventional imaging in primary staging 50One study showed poorer diagnostic accuracy when compared with PSMA-PET in biochemical recurrence with a low PSA (48) Not widely utilised at present. There is increasing evidence to support its use in assessing disease response especially in bony metastases (51,52) CT, computed tomography; EAU, European Association of Urology; LN, lymph node; MRI, magnetic resonance imaging; NaF, sodium fluoride; NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen test; PSMA, prostate-specific membrane antigen; PET, positron emission tomography; WB-MRI, whole-body magnetic resonance imaging.…”

Section: Systemic Therapiesmentioning

confidence: 99%

A narrative review of oligometastatic prostate cancer—an evolving paradigm

Sritharan¹,

Rieu²,

Tree³

2021

Ann Palliat Med

View full text Add to dashboard Cite

There has been growing interest in oligometastatic prostate cancer (OMPC) with a mounting body of evidence to suggest that it is a distinct disease state, both biologically and prognostically, when compared to polymetastatic prostate cancer. Three subgroups have been recognised; de novo synchronous, metachronous/oligorecurrent and oligoprogressive disease. The belief that patients with OMPC can be treated more aggressively to improve survival is transforming patient care. Identifying these patients poses the first challenge, and we explore the imaging modalities currently utilised and those that are promising. For patients with de novo synchronous OMPC, both early systemic treatment in addition to androgen deprivation therapy (ADT) and radiotherapy to the prostate increase overall survival (OS), and both are increasingly being integrated into routine clinical practice. Metastasis-directed therapy (MDT) has predominantly been delivered using stereotactic body radiotherapy (SBRT) in prostate cancer and studies have shown SBRT is well-tolerated, provides excellent local control and can be used to delay ADT in the metachronous setting. We discuss the current management strategies in OMPC, review the evidence supporting the use of SBRT and outline ongoing trials.

show abstract

“…4 PSMA-targeted molecular imaging have been approved to be a better diagnostic tool in patients with prostate cancer than conventional imaging. 5 However, the clinical data focusing on the predictive value of PSMA imaging for primary localized prostate cancer patients treated with radiotherapy (especially CIRT) was limited. In addition, our primary study shown that apparent diffusion coefficient (ADC) vales may be an useful imaging bio-marker for early assessment of therapeutic response of prostate cancer to CIRT.…”

Section: Introductionmentioning

confidence: 99%

Combination of 99mTc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study

Li¹,

Liu

Wu³

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose The purpose of this study was to assess the potential of 99m Tc-labeled PSMA-SPECT/CT and diffusion-weighted image (DWI) for predicting treatment response after carbon ion radiotherapy (CIRT) in prostate cancer. Patients and Methods We prospectively registered 26 patients with localized prostate cancer treated with CIRT. All patients underwent 99m Tc-labeled PSMA-SPECT/CT and multiparametric magnetic resonance imaging (MRI) before and after CIRT. The tumor/background ratio (TBR) and mean apparent diffusion coefficient (ADC mean ) were measured on the tumor and the percentage changes before and after therapy (ΔTBR and ΔADC mean ) were calculated. Patients were divided into two groups: good response and poor response according to clinical follow-up. Results The median follow up time was 38.3months. The TBR was significantly decreased ( p =0.001), while the ADC mean was significantly increased compared with the pretreatment value ( p <0.001). The ΔTBR and ΔADC mean were negatively correlated with each other ( p = 0.002). On ROC curve analysis for predicting treatment response, the area under the ROC curve (AUC) of ΔTBR (0.867) for predicting good response was higher than that of ΔADC mean (0.819). The AUC of combined with ΔTBR and ΔADC mean (0.895) was higher than that of either ΔADC mean or ΔTBR alone. The combined use of ΔTBR and ΔADC mean showed 91.4% sensitivity and 95.2% specificity. Conclusion Our preliminary data indicate that the changes of TBR and ADC mean maybe an early bio-marker for predicting prognosis after CIRT in localized prostate cancer patients. In addition, the ΔTBR seems to be a more powerful prognostic factor than ΔADC mean in prostate cancer treated with CIRT.

show abstract

Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy

Cited by 53 publications

References 37 publications

Whole‐body diffusion‐weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond

Whole‐body diffusion‐weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond

A narrative review of oligometastatic prostate cancer—an evolving paradigm

Combination of 99mTc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study

Contact Info

Product

Resources

About